Identification of a small compound targeting cancer stem cells in cholangiocarcinoma

• Project/Area Number: 17K10716
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: Yamamoto Kuniharu 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (00375073)
• Co-Investigator(Kenkyū-buntansha): 玉井 恵一 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 部長 (40509262)
• Project Period (FY): 2017-04-01 – 2021-03-31
• Project Status: Completed (Fiscal Year 2020)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 胆管癌 / がん幹細胞

Outline of Final Research Achievements

Recently, Cancer stem cell is recognized as therapy-resistant cells because its population is dominant in quiescent phase. We searched a new cancer stem cell-related gene, and found BEX2. BEX2 is indispensable in maintaining dormant cancer stem cells and could be a promising therapeutic target.

Academic Significance and Societal Importance of the Research Achievements

私たちは難治性癌である胆管癌の新たな治療標的を同定した。今後、詳細な分子機構を明らかにすることで、新規治療に結びつく可能性がある。

Research Products

• [Journal Article] BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma (2020)
  • Author(s): Tamai Keiichi、Nakamura-Shima Mao、Shibuya-Takahashi Rie、Kanno Shin-Ichiro、Yasui Akira、Mochizuki Mai、Iwai Wataru、Wakui Yuta、Abue Makoto、Yamamoto Kuniharu、Miura Koh、Mizuma Masamichi、Unno Michiaki、Kawamura Sadafumi、Sato Ikuro、Yasuda Jun、Yamaguchi Kazunori、Sugamura Kazuo、Satoh Kennichi
  • Journal Title: Scientific Reports Volume: 10 Issue: 1 Pages: 21592-21592
  • DOI: 10.1038/s41598-020-78539-0
  • Peer Reviewed / Open Access
• [Journal Article] CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells (2020)
  • Author(s): Hatsuzawa Yuuri、Yamaguchi Kazunori、Takanashi Tomoka、Sato Ikuro、Tamai Keiichi、Mochizuki Mai、Iwai Wataru、Wakui Yuta、Abue Makoto、Yamamoto Kuniharu、Yasuda Jun、Mizuma Masamichi、Unno Michiaki、Sugamura Kazuo
  • Journal Title: Pancreatology Volume: 20 Issue: 3 Pages: 493-500
  • DOI: 10.1016/j.pan.2020.01.013
  • Peer Reviewed
• [Journal Article] Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species (2018)
  • Author(s): Yokoyama Misa、Tanuma Nobuhiro、Shibuya Rie、Shiroki Takeharu、Abue Makoto、Yamamoto Kuniharu、Miura Koh、Yamaguchi Kazunori、Sato Ikuro、Tamai Keiichi、Satoh Kennichi
  • Journal Title: International Journal of Oncology Volume: 52 Pages: 881-891
  • DOI: 10.3892/ijo.2018.4258
  • Peer Reviewed